As lateral flow technology advances and the demand for rapid diagnosis increases so does the demand for more advanced capabilities from the technology.
In this final edition of our series exploring the expected growth of the lateral flow diagnostics market (8.2% CAGR by 2022. Markets and Markets 2017), we discuss the latest stage in the evolution of lateral flow technology, quantitation.
By 2022, reports have suggested the quantitative lateral flow market will be valued at $1.2bn, which is a CAGR of 8.5% from 2017.
Lateral flow quantitation is achieved by using lateral flow readers and image processing algorithms, specific to a particular test type, to correlate lateral flow test lines with analyte concentrations. As well as quantitation readers can determine thresholds, ratios and maximum limits.
There are a variety of lateral flow readers on the market which can read single or multiple strips or cassettes, with single or multiple biomarkers incorporated. Lateral flow readers divide into:
Requiring a mains power supply these systems are primarily used in laboratory settings, clinics, or mobile testing centres. Desktop readers are often larger to enable a stable platform, with an easy to use, clear and visible user interface, offering robust, rapid, and sensitive quantification of lateral flow assays. Desktop readers often come with full flexibility for data connectivity such as USB, LAN, Wi-Fi, Bluetooth.
Where a portable, in-field, solution is required compact hand-held lateral flow readers are available. These can be smaller versions of the desktop systems with a simpler and smaller user interface or can be custom built applications (Apps) within Smartphones.
The increasing demand by GPs, clinicians, veterinarians, farmers and food safety professionals, to generate real-time results, enabling rapid decision making, is driving the decentralisation of laboratory testing. Reader technology is an essential tool for generating and storing real-time results, whether that be simple qualitative or more complex quantitative results with associated algorithms.
The improvement in reading optics, camera technology, connectivity and computer processing, coupled with data storage and transfer, is improving the performance of these diagnostic solutions and increasing demand for quantitative lateral flow assays. An example being the use of Seralite® – FLC, which measures kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in order to aid the diagnosis and management of patients with multiple myeloma (blood cancer).
Abingdon has developed the ADxLR5® desktop reader, which is used alongside our own products, as well as being made available to contract customers who require a quantitative testing solution.
The benefits of the ADxLR5® include:
In addition, Abingdon collaborates closely with hand-held reader technology companies.
Further details can be found:
Desktop reader: http://www.abingdonhealth.com/contract-services/lateral-flow-reader/adxlr5/
Smartphone reader: http://www.abingdonhealth.com/contract-services/lateral-flow-reader/appdx/
Lateral flow technology is highly adaptable to multiple testing scenarios providing the following benefits:
The world is becoming a fast-moving and populous place with social, economic and environmental factors influencing the need and demand for rapidity in a multitude of areas including testing and diagnostics.
Throughout this series of articles, there has been a reoccurring theme in that healthcare, animal health and agri-food professionals want to carry out their roles in an accurate, cost-effective and time-efficient manner in response to demand. Conversely, the market wants to be recipients of rapid and early diagnosis, or detection, and of course subsequent treatments, solutions or care packages.
This is why testing and diagnostic professionals across the different sectors are turning to lateral flow technology. The evolution of assay and reader technology, coupled with development and manufacturing capabilities, is allowing professionals, even in regulated markets, to meet the demands of stakeholders.
Knowing the capabilities of lateral flow technology and the potential technological evolution, it goes some way to explaining why lateral flow diagnostics market is expected to grow as it is.
You can see our series of article by clicking on one of the links below:
Abingdon Health has a long-track record of developing and manufacturing single target and multiplex lateral flow assays, both qualitative and quantitative, within regulated and non-regulated markets. Watch one of our videos or contact us to learn more about our capabilities.
Published 26th April 2018
© Abingdon Health 2019